Neural Network Enhanced Structure Determination of Osteoporosis, Immune System, and Radiation Repair Proteins, Phase I

The proposed innovation will utilize self learning neural network technology to determine the structure of osteoporosis, immune system disease, and excess radiation DNA damage target proteins that will facilitate drug development to enhance crew health in long term space flight missions. This system is innovative because: 1) the proprietary neural networks will provide a unique understanding of the often non-linear crystallization process of the targets; 2) the system will objectively utilize the osmotic second virial coefficient to identify optimal screen components; 3) a commercial predictive database will be developed that may eliminate the need for initial crystallization screening and increase the rate of structure determination thus offering tremendous commercial potential as a fee based service. This dual use innovation is applicable to subtopic B4.01 Space Commercialization because this approach will focus on the development of osteoporosis, immune system disease, and excess radiation DNA repair targets which will improve crew health on long term space missions and will provide an earth-based commercial service to drug discovery entities.

This is a mature technology (TRL 7+) — the realistic path in is usually NASA's Technology Transfer Program: licensing an existing NASA patent, or a Space Act Agreement to use NASA facilities/expertise directly. NASA also runs a startup licensing program with no upfront fee for companies formed to commercialize a specific NASA technology.

None of these are guaranteed paths for this specific project — TechPort itself doesn't have an "apply" button. Reaching out to the contact(s) above with a specific question is usually the fastest way to find out what's actually open.